The ACP6 Knockout HT29 Polyclonal Cells represent a polyclonal population of the HT29 human colorectal adenocarcinoma cell line subjected to CRISPR/Cas9-mediated disruption of the ACP6 gene. This knockout model eliminates functional ACP6 expression across the population without selection for clonal homogeneity, providing a heterogeneous loss-of-function system suitable for studies of lipid phosphatase activity and LPA signaling dynamics. The product is supplied as a pool of gene-edited cells, enabling robust experimental throughput while capturing cellular variability inherent to polyclonal cultures. Researchers can employ these cells to dissect the consequences of ACP6 ablation in a genetically unselected background, mimicking natural tumor heterogeneity.
HT29 cells were originally established from a primary colorectal adenocarcinoma of a 44-year-old Caucasian female. This cell line has been widely adopted as an intestinal epithelial model and a cornerstone of colorectal cancer research. HT29 cells exhibit adherent epithelial morphology and retain characteristics of moderately differentiated adenocarcinoma, including the ability to form glandular structures and express intestinal markers. They are commonly used to study colorectal tumor biology, drug responses, and signal transduction pathways. The HT29 background provides a clinically relevant context for interrogating oncogenic signaling, as these cells harbor mutations in APC, TP53, and other oncogenic drivers, reflecting the genomic landscape of sporadic colorectal cancer.
ACP6 encodes a lysophosphatidic acid (LPA) phosphatase that hydrolyzes extracellular and intracellular LPA, converting it to monoacylglycerol and thereby attenuating LPA-mediated signaling. LPA is a bioactive lipid that predominantly signals through six cognate G protein-coupled receptors (LPAR1-6). Downstream effectors include heterotrimeric G proteins such as G??12/13, leading to activation of RhoA and ROCK, as well as Ras-mediated stimulation of the MAPK/ERK cascade and PI3K-dependent AKT phosphorylation. ACP6 thus functions as a negative regulator of LPA availability. Knockout of ACP6 is expected to elevate local LPA concentrations, resulting in sustained LPAR engagement, enhanced Rho GTPase signaling, and amplified ERK and AKT activation. These pathways collectively drive cytoskeletal remodeling, proliferation, migration, and survival??processes critically implicated in colorectal cancer progression.
In HT29 colorectal cancer cells, loss of ACP6 creates a hyperactive LPA signaling environment that mirrors aspects of aggressive tumor phenotypes. Elevated LPA levels potentiate LPAR-mediated pathways that are already dysregulated in colorectal carcinogenesis. For example, increased RhoA-ROCK signaling promotes actomyosin contractility and mesenchymal-like invasion, while sustained ERK and AKT activation supports anchorage-independent growth and resistance to apoptosis. This model enables dissection of how lipid phosphatase deficiency cooperates with pre-existing oncogenic mutations in HT29 cells. It also provides a unique tool for evaluating the dependency of colorectal cancer cells on LPA-driven circuits and for testing inhibitors targeting LPARs or downstream kinases.
Typical applications include quantifying LPA accumulation by LC-MS, measuring phospho-ERK and phospho-AKT levels via western blotting, conducting Transwell migration and invasion assays, and performing cell proliferation (MTT) and colony formation studies. The polyclonal ACP6 knockout HT29 cells are well-suited for drug target validation in LPA-related signaling, functional genomics screens, and investigating the role of lipid phosphatases in tumor microenvironmental interactions. Researchers focusing on hereditary spastic paraplegia or LPA-associated disorders may also leverage these cells to model neurological disease aspects, given the emerging links between lipid metabolism and neurodegeneration. For custom experimental design or additional product specifications, please contact Ascent Research.
